PBPK Model Describes the Effects of Comedication and Genetic Polymorphism on Systemic Exposure of Drugs That Undergo Multiple Clearance Pathways

Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug

(2013) Md L T Vieira et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Utility of Modeling and Simulation in Drug Development and Regulatory Review

(2013) Shiew-Mei Huang et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time-Dependent CYP3A Inhibitor

(2012) Md L T Vieira et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions

(2012) P Zhao et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS-690514 in Healthy Participants: Assessing the Mechanism of the Interaction With Physiologically-Based Pharmacokinetic Simulations

(2012) Zheng Yang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

BDDCS Applied to Over 900 Drugs

(2011) Leslie Z. Benet et al.   AAPS Journal

Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science

(2011) Malcolm Rowland et al.   Annual Review of Pharmacology and Toxicology

Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers

(2011) Bimal Malhotra et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects

(2011) Bimal Malhotra et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction

(2011) M. Gertz et al.   DRUG METABOLISM AND DISPOSITION

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine

(2011) Junichi Azuma et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers

(2011) W. Mahatthanatrakul et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review

(2010) P Zhao et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions

(2010) E. J. Guest et al.   DRUG METABOLISM AND DISPOSITION

Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors

(2010) Y.-H. Wang   DRUG METABOLISM AND DISPOSITION

Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

(2009) Shu-Feng Zhou   CLINICAL PHARMACOKINETICS

Macrolide-Induced Digoxin Toxicity: A Population-Based Study

(2009) T Gomes et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction

(2009) O. A. Fahmi et al.   DRUG METABOLISM AND DISPOSITION

Application of CYP3A4 in vitro data to predict clinical drug–drug interactions; predictions of compounds as objects of interaction

(2008) Kuresh A. Youdim et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY